ID: ALA4860779

Max Phase: Preclinical

Molecular Formula: C22H19F2N5

Molecular Weight: 391.43

Molecule Type: Unknown

Representations

Canonical SMILES:  FC(F)c1cncc(-c2ccc3ncc4nnc(C5=CCCCCC5)n4c3c2)c1

Standard InChI:  InChI=1S/C22H19F2N5/c23-21(24)17-9-16(11-25-12-17)15-7-8-18-19(10-15)29-20(13-26-18)27-28-22(29)14-5-3-1-2-4-6-14/h5,7-13,21H,1-4,6H2

Standard InChI Key:  GCHBEJBYMQHZEM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 391.43

Molecular Weight (Monoisotopic): 391.1609

AlogP: 5.62

#Rotatable Bonds: 3

Polar Surface Area: 55.97

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 4.01

CX LogP: 3.48

CX LogD: 3.47

Aromatic Rings: 4

Heavy Atoms: 29

QED Weighted: 0.45

Np Likeness Score: -1.18

References

1. Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G..  (2021)  BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.,  64  (17.0): [PMID:34428039] [10.1021/acs.jmedchem.1c00762]

Source

Source(1):

• Scientific Literature